Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ('Pom‐PAD‐Dara') in relapsed/refractory multiple myeloma

Autor: Zhou, Xiang, Steinhardt, Maximilian J., Grathwohl, Denise, Meckel, Katharina, Nickel, Katharina, Leicht, Hans‐Benno, Krummenast, Franziska, Einsele, Hermann, Rasche, Leo, Kortüm, Klaus M.

Publikováno v: Cancer Medicine, Vol 9, Iss 16, Pp 5819-5826 (2020)
Cancer Medicine

Background Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f4809852a9d120ba4dc1dcc4587f791f
https://doaj.org/article/de8c2d8802274012a1aac441c04130c1

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Autor: Steinhardt, Maximilian Johannes, Zhou, Xiang, Krummenast, Franziska, Meckel, Katharina, Nickel, Katharina, Böckle, David, Messerschmidt, Janin, Knorz, Sebastian, Dierks, Alexander, Heidemeier, Anke, Lapa, Constantin, Einsele, Hermann, Rasche, Leo, Kortüm, Klaus Martin

Publikováno v: International Journal of Immunopathology and Pharmacology

We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8b653ce626722269aceeaa86adf131b2
https://doi.org/10.1177/2058738420980258

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.

Autor: Steinhardt MJ; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Zhou X; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Krummenast F; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Meckel K; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Nickel K; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Böckle D; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Messerschmidt J; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Knorz S; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Dierks A; Department of Nuclear Medicine, University Hospital Würzburg, Wurzburg, Germany.; Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany., Heidemeier A; Department of Diagnostic Radiology, University Hospital Würzburg, Wurzburg, Germany., Lapa C; Department of Nuclear Medicine, University Hospital Würzburg, Wurzburg, Germany.; Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany., Einsele H; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany., Rasche L; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany.; Mildred Scheel Early Career Center, University Hospital of Würzburg, Würzburg, Germany., Kortüm KM; Department of Oncology and Hematology, University Hospital Würzburg, Wurzburg, Germany.

Publikováno v: International journal of immunopathology and pharmacology [Int J Immunopathol Pharmacol] 2020 Jan-Dec; Vol. 34, pp. 2058738420980258.